US 12215131
IgG Fc-IL2-Rα-IL2 fusions and methods of use thereof
granted A61KA61K2039/505A61K2039/585
Quick answer
US patent 12215131 (IgG Fc-IL2-Rα-IL2 fusions and methods of use thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 25
- CPC classes
- A61K, A61K2039/505, A61K2039/585, A61K2239/50, A61K2239/55